Irinotecan Accord

Irinotecan, the active ingredient in Irinotecan Accord, is a topoisomerase I inhibitor presented as an injectable solution for intravenous use. It is employed in the treatment of metastatic colorectal cancer, targeting adult patients whose disease has progressed despite prior therapy, and is administered under the supervision of qualified oncology specialists.

GNH USA supplies Irinotecan Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide, providing consistent quality and regulatory‑aligned documentation for global procurement and supporting timely delivery to meet clinical schedules.

Irinotecan is a topoisomerase I inhibitor used in oncology for colorectal cancer management.

Metastatic colorectal cancer: used in combination regimens to extend survival. Refractory colorectal cancer: employed when disease progresses after first‑line treatment. Advanced colorectal cancer: part of second‑line therapy to control tumor growth.

Irinotecan may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Diarrhea: frequent watery stools that may require antidiarrheal therapy. - Nausea and vomiting: gastrointestinal upset common during treatment. - Fatigue: persistent tiredness affecting daily activities. - Neutropenia: reduced white blood cell count increasing infection risk.

Serious or Rare Side Effects: - Severe neutropenia with fever: may lead to life‑threatening infection. - Colitis or severe diarrhea: can cause dehydration and electrolyte imbalance. - Hepatotoxicity: elevated liver enzymes indicating liver injury. - Allergic reactions: rash, bronchospasm, or anaphylaxis in rare cases.

Before and during treatment, several safety measures should be observed.

Blood count monitoring: perform complete blood count before each cycle. Liver function assessment: check transaminases and bilirubin regularly. Bowel health evaluation: assess for pre‑existing diarrhea or obstruction. Hypersensitivity screening: discontinue if signs of allergic reaction appear. Dose adjustment: consider reduced dose in patients with moderate hepatic impairment. Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Irinotecan interacts with several drug classes that may alter its efficacy or toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce irinotecan exposure. - Anticholinergic agents used for prophylaxis: can increase risk of severe diarrhea. - Concomitant use with other topoisomerase I inhibitors: additive toxicity.

Moderate Interactions (Monitor Closely): - UGT1A1 inhibitors (e.g., atazanavir): may increase active metabolite levels, requiring dose adjustment. - Anticoagulants (e.g., warfarin): monitor INR as irinotecan may affect coagulation parameters.